Related Experiment Video

Updated: Aug 24, 2026

Semi-automated Optical Heartbeat Analysis of Small Hearts
12:10

Semi-automated Optical Heartbeat Analysis of Small Hearts

Published on: September 16, 2009

American Heart Association scientific sessions

Bernhard R Winkelmann1

  • 1University of Heidelberg, Germany. bernhard.winkelmann@med.uni-heidelberg.de

Expert Opinion on Investigational Drugs
|April 23, 2004
PubMed

Insights

The Valsartan in Acute Myocardial Infarction Trial (VALIANT) found valsartan and captopril equally effective for heart attack survivors. Combining them offered no extra benefit but increased side effects.

Area of Science:

  • Cardiovascular Medicine
  • Clinical Trials
  • Pharmacology

Background:

  • Presents key findings from late-breaking clinical trials at the American Heart Association Annual Scientific Sessions.
  • Focuses on major cardiovascular research impacting clinical practice.

Framework:

  • The Valsartan in Acute Myocardial Infarction Trial (VALIANT) compared valsartan, captopril, and their combination in post-myocardial infarction patients.
  • Evaluated clinical outcomes, efficacy, and safety profiles of these cardiovascular medications.

Implementation:

  • VALIANT demonstrated equal efficacy between valsartan and captopril.
  • The combination therapy showed no additional clinical benefit and a higher risk of adverse events.

Implications:

  • VALIANT is a landmark study, being the first large trial to compare ARB/ACE inhibitor combination in acute myocardial infarction.
  • Highlights the importance of individualized treatment strategies and risk-benefit assessments in cardiovascular care.

More Related Videos

Slicing and Culturing Pig Hearts under Physiological Conditions07:54

Slicing and Culturing Pig Hearts under Physiological Conditions

Published on: March 20, 2020

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...